ADAnnemieke Dhondt

Annemieke Dhondt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annemieke Dhondt has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PULSATING TUMOUR IN THE CLAVICULAR REGION OF A CHRONIC HAEMODIALYSIS PATIENT WITH IPSILATERAL VASCULAR ACCESS CATHETER

    by L.-M. Reyns, A. Dhondt, M. Petrovic, D. Voet, R. Vanholder

    We describe the case of a 70-year-old woman who presented with a pulsating mass in the left supraclavicular region during a haemodialysis session. The frequency of the pulsations, parallel to that of the dialysis-related blood flow cycle, without blood loss at the exit site, indicated that this observation could potentially be attributed to a rupture of the silastic material in the subcutaneous track of the catheter. Our hypothesis was confirmed after removal of the catheter.


  • The removal of uremic toxins

    by Annemieke Dhondt, Raymond Vanholder, Wim Van Biesen, Norbert Lameire


    • 1 October 1998
      • Vol. 9  (10) , 1826-31

    Inhibition of calcitriol-induced monocyte CD14 expression by uremic toxins: role of purines.

    by G Glorieux, C H Hsu, R De Smet, A Dhondt, J Van Kaer, P Vogeleere, N Lameire, R Vanholder

    End-stage renal disease is associated with a defect in immunologic functions. Previous studies have demonstrated that uremic ultrafiltrate (UUF) contains factors that suppress calcitriol synthesis and its biological actions. In the present study, the effect of UUF on basal and calcitriol-induced membrane bound CD14 expression of monocytes activated by phorbol 12-myristate 13-acetate was evaluated. CD14 acts as a receptor for the complexes of lipopolysaccharide and lipopolysaccharide-binding protein. Monocytes isolated from normal donors were used for the assay of monocyte CD14 expression. A calcitriol induced rise in monocyte CD14 expression (1966+/-423 to 2421+/-436 fluorescence intensity) was found. However, UUF not only suppressed basal CD14 expression of monocytes (from 1966+/-423 to 1240+/-203, P < 0.05) but also significantly blunted calcitriol-induced CD14 expression (from 2421+/-436 to 1744+/-229, P < 0.05). HPLC fractionated UUF collected from 8 to 16 min (fraction 1, F1) and from 25 to 40 min (fraction 3, F3) also significantly suppressed the expression of CD14. Because purine derivatives coeluted within F1, their effect on monocyte CD14 expression was also tested. Uric acid, xanthine, and hypoxanthine was found to suppress basal as well as calcitriol-induced CD14 expression of monocytes in a dose-dependent manner. In conclusion, UUF contains factors that impair calcitriol activated function of monocytes.


    • 1 January 1998
      • Vol. 49  (1) , 41-4

    Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.

    by N Veys, A Dhondt, N Lameire

    Patients may complain of pain at the injection site after subcutaneous (s.c.) administration of erythropoietin (EPO). Local pain due to s.c. EPO into the thigh was evaluated in 60 hemodialysis patients in a double-blind, placebo-controlled study. Identical volumes and concentrations (2000 IU in 0.5 ml) of phosphate-buffered epoetin-alpha (EPO-alpha ph), citrate-buffered epoetin-alpha (EPO-alpha ci) and epoetin-beta (EPO-beta) were compared to 0.5 ml of 0.9% saline (SAL), used as placebo. The patients received the 4 injections at the same occasion. For pain evaluation, a verbal scale ranging from no pain (0) to extremely painful (5) and a 10 cm ungraduated visual analogue score (VAS) (0 = no pain, 10 = maximal pain) were used. Treatment acceptance was assessed (yes/no) and expressed as a percentage of the population. Ranking of the preparations from 1 to 4 according to increasing local discomfort was performed. Median verbal pain scores and interquartile ranges were 1.0 (0-2) for SAL, 0.0 (0-2) for EPO-beta, 1.5 (0-3) for EPO-alpha ph (p < or = 0.05 vs SAL and EPO-beta) and 3.0 (2-4) for EPO-alpha ci (p < or = 0.001 vs EPO-alpha ph). VAS was 0.9 (0.5-2.5) for SAL, 0.9 (0.4-2.4) for EPO-beta, 2.7 (0.8-5.7) for EPO-alpha ph (p < or = 0.001 vs SAL and EPO-beta) and 4.2 (1.7-6.4) for EPO-alpha ci (p < or = 0.001 vs EPO-alpha ph). Treatment acceptance was 73% for SAL, 78% for EPO-beta, 60% for EPO-alpha ph (p < or = 0.05 vs EPO-beta) and 32% for EPO-alpha ci (p < or = 0.05 vs EPO-alpha ph). Ranking was 2 (1-3) for SAL, 2 (1-2) for EPO-beta, 3 (1-4) for EPO-alpha ph (p < or = 0.05 vs SAL and EPO-beta) and 4 (3-4) for EPO-alpha ci (p < or = 0.05 vs SAL and EPO-beta) and 4 (3-4) for EPO-alpha ci (p < or = 0.001 vs EPO-alpha ph). In conclusion, s.c. EPO-alpha ph is better accepted than s.c. EPO-alpha ci. However, s.c. EPO-beta is less painful.


  • Different Types of Dialyzer Membranes: Does the Bio(in)compatibility Matter in the Treatment of ARF?

    by R. Vanholder, N. Lameire, E. Hoste, A. Van Loo, A. M. Dhondt, S. Ringoir


    • 1 January 1995
      • Vol. 10  (3) , 414-8

    Second symposium on uraemic toxicity. Summary of a symposium held in Gent, Belgium, 22-24 September 1994.

    by R Vanholder, A Van Loo, A M Dhondt, G Glorieux, R De Smet, S Ringoir

    • 1 July 1988
      • Vol. 34  (3) , 543-5

    Challenge of phagocyte metabolism by extracorporeal circulation and membrane contact. A biocompatibility test.

    by R C Vanholder, A Dhondt, S M Ringoir

    In the present study, direct data on phagocyte metabolism during hemodialysis are collected by the determination of 14CO2-production from labelled glucose on whole blood samples. Fifteen minutes after the start of cuprophan dialysis, 14CO2 production per 10(3) phagocytes increased more than four-fold (from 77.6 +/- 30.2 to 315.0 +/- 69.6 DPM/10(3) phagocytes; P less than 0.01). Such a change was absent during dialysis with membranes containing polysulphone, AN69S or reused cuprophan. In vitro contact of normal blood with cuprophan membranes revealed an increase of 14CO2-production by a maximum of 9.0 +/- 3.4 X 10(3) D.P.M. at 15 min. (P less than 0.05). Such an increase was absent after contact with polysulphone. The measurement of 14CO2 production during glucose metabolism, by phagocytes present in micro-amounts of whole blood, is a valuable test for membrane biocompatibility. Cuprophan dialysis induces a challenge of phagocytic activity that is absent for dialysers containing other membranes.